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Abstract
Background: Epidermal growth factor receptor (EGFR) activation plays a role in colorectal cancer (CRC) carcinogenesis, and
anti-EGFR drugs are used in treatment of advanced CRC. One of the EGFR ligands is tumor-associated trypsinogen inhibitor
TATI, also called serine protease inhibitor Kazal type1 (SPINK 1), which we recently showed to be an independent prognostic
marker in CRC.
Methods: We studied the prognostic value of immunohistochemical expression of EGFR and concomitant expression of
EGFR and TATI/SPINK1 in a series of 619 colorectal cancer patients.
Results: Of the samples, 92% were positive for EGFR. EGFR+/TATI+ was seen in 62.8%, EGFR+/TATI2 in 29.5%, EGFR2/TATI+
in 4.9%, and EGFR2/TATI2 in 2.7% of patients. EGFR expression correlated with WHO grade (p = 0.040). In univariate
analysis, EGFR expression correlated with favourable survival (p = 0.006). EGFR+/TATI+ patients showed better survival than
did those with other combinations (p,0.001). In multivariate analysis, EGFR+/TATI+ was an independent prognostic factor
of favourable prognosis (p,0.001).
Conclusion: Concomitant positivity of EGFR and TATI/SPINK1 predicts favourable prognosis in CRC.
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Introduction
Colorectal cancer (CRC) is the world’s third most common
malignancy [1],[2]. In Finland, the incidence is 30/100 000/year
[3]. The most important prognostic factor in CRC is tumour
stage.
Prognosis of patients with local CRC is good, 5-year survival
being 80–90%, for node-positive tumors it is 60–70%, while for
tumors with distant metastases it is less than 10%) [4–6]. Patients
with stage III–IV (Dukes’ C and D) disease usually receive
adjuvant chemotherapy. In stage II (Dukes’ B) disease, chemo-
therapy is not routinely used although some of these patients
obviously would benefit from adjuvant therapy. To identify
patients at high risk requires additional prognostic factors like
biomarkers.
The epidermal growth factor receptor (EGFR), a target for
treatment of advanced colorectal cancer, belongs to a transmem-
brane glycoprotein of the ErbB tyrosine kinase receptor family.
Ligand-receptor interaction and dimerization of the receptor leads
to tyrosine autophosphorylation, activating an intracellular signal
pathway that promotes cell division and migration, inhibition of
apoptosis, and angiogenesis [7]. The monoclonal antibodies
cetuximab and panitumumab bind to EGFR and disable the
activation of tyrosine-kinase and downstream signalling pathways.
Mutations in the molecular pathways activated via EGFR can
contribute to carcinogenesis. In CRC, the most frequent mutations
concern the KRAS gene occurs in about 40% of CRC cases
[8],[9]. The mutations deactivate guanosine triphosphatase
(GTPase) activity, leading to accumulation of activated KRAS.
These KRAS mutations lead to lack of response to anti-EGFR
therapy [10],[11].
Along with EGF, amphiregulin, transforming growth factor
(TGF) a, epiregulin, betacellulin, heparin-binding EGF, and
epigen activate EGFR [12]. Recently in pancreatic adenocarci-
nomas, serine protease inhibitor Kazal type1 (SPINK 1), also
called pancreatic secretory trypsin inhibitor (PSTI) and tumour-
associated trypsinogen inhibitor (TATI), was shown to activate
EGFR [13]. TATI/SPINK1 is expressed together with EGFR in
pancreatic adenocarcinomas. EGF and TATI/SPINK1 share
about 50% amino acid homology [14], and the binding affinity of
TATI/SPINK1 to EGFR is about half that of that of EGF [13].
We have recently shown that tissue expression of TATI/
SPINK1 is an indicator of favourable prognosis in colorectal
cancer patients [15]. In the present study we evaluated the
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relationship between EGFR and TATI expression and its possible
prognostic value in colorectal cancer.
Materials and Methods
Patients
Clinical data were available from 643 consecutive patients who
underwent surgery for histologically confirmed colorectal cancer at
the Department of Surgery, Meilahti Hospital, Helsinki University
Central Hospital, between 1982 and 1998. Complete clinical data
and archival tissue specimens were available from 623 cases, 333
of them male. Median age was 65.9 years (range 22.7–90.3), and
median follow-up time 4.81 years (range 0–25.8). Survival and
cause of death data until March 2011 were obtained from the
Population Register Centre of Finland, and Statistics Finland.
Diagnosis and staging were performed according to the modified
Dukes’ classification [16]. The study has been approved by local
ethics committee and complies with the Declaration of Helsinki
(Dnro HUS 226/E6/06) and the National Supervisory Authority
for Welfare and Health. Clinicopathological characteristics of the
patients are described in Table 1.
Tissue samples and preparation of TMA blocks
Formalin-fixed and paraffin-embedded surgical tissue samples
were collected from the archives of Department of Pathology,
University of Helsinki. Histopathologically representative regions
of tumour specimens were defined and marked on H&E slides.
Three cores from each tumour block were sampled with 1.0 mm
punchers by use of a semiautomatic tissue microarrayer (Tissue
Arrayer 1, Beecher Instruments Inc., Silver Spring, MD, USA).
Three parallel serial blocks were constructed, all including one
sample from each patient. From each block, 4 mm thick sections
were cut for immunohistochemistry.
Immunohistochemistry
The Lab Vision Autostainer TM 480 (LabVision, Fremont, CA,
USA) was used for immunostaining. Tissue sections were
deparaffinized in xylene and rehydrated through graded alcohol
series. To retrieve antigens, samples were heated in the
pretreatment module of the autostainer in pre-heated TRIS-
EDTA pH 9.0 buffer for 20 min at 98uC. The samples were
incubated for 5 min in DAKO REAL Peroxidase–Blocking
Solution (DAKO, Glostrup, Denmark) for inactivation of endog-
enous peroxidases. The sections were incubated for 60 min with
primary monoclonal NCL-EGFR antibody (clone 113) against the
extracellular domain, which stains both membrane and cyto-
plasma (Novo Castra, Newcastle, UK, dilution 1:10). The sections
were reacted for 30 min with HRP link and for 30 min with HRP
enzyme (anti-mouse-anti-rabbit labelled polymer) (DAKO, Car-
pinteria, CA, USA). Between each of the steps the sections were
rinsed with Tween 20-PBS (phosphate-buffered sodium chloride
buffer, pH 9.0). Then the samples were incubated for 10 min in
the DAB + EnVision System (DAKO, Glostrup, Denmark), and
stained with hematoxylin for 1 minute. Finally the samples were
rinsed in running tap water. Immunostaining of TATI was
performed as described (Koskensalo 2011).
Table 1. Patient clinicopathological characteristics and their
correlation with EGFR immunoreactivity in 520 colorectal
cancer patients assessed with chi-square test (a Mann-Whitney
test).
Clinicopathological Patients positive p -value
variable (n) %
Gender 0.890
Female 235 216 91.9
Male 285 261 91.6
Age 0.972
,65 years 219 201 91.7
$65 years 301 276 91.7
range 25.0–90.3,
median 67.6 years
0.991
Dukes’ stage 0.145
A 81 77 95.1
B 188 177 94.1
C 126 112 88.9
D 125 111 88.8
Dukes’ stage 0.021*
A and B 269 254 94.4
C and D 251 223 88.8
Differentiation (WHO grade) 0.040* (Fishers’)
1 17 16 94.1
2 351 330 94.0
3 130 113 86.9
4 21 18 85.7
missing 1
Histologic type 0.244
Adenocarcinoma 463 427 92.2
Mucinous carcinoma 57 50 87.7
Tumor location 0.948
Colon 291 267 91.8
Rectum 226 207 91.6
missing 3
* =p-value significant.
doi:10.1371/journal.pone.0076906.t001
Figure 1. Immunohistochemical scoring pattern of EGFR and
TATI/SPINK1 in colorectal cancer. A. EGFR positive, B. EGFR
negative, C. TATI/SPINK1 positive, D. TATI/SPINK1 negative immunoex-
pression.
doi:10.1371/journal.pone.0076906.g001
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Scoring
EGFR cytoplasmic immunopositivity in tumour cells was scored
by two independent investigators (S.K. and J.H.) without
knowledge of clinical outcome. Cytoplasmic EGFR immunoposi-
tivity was evaluated by percentage of positively stained cells.
Positivity in over 50% of cells was scored as 3, 10–50% as 2, and
less than 10% as 1 (Figure 1). Absence of positivity was scored as 0.
Tissue spots without tumour cells were excluded. The highest
score was used for each patient. For statistical analysis, the patients
were divided into two groups: EGFR2 (score 0) and EGFR+
(scores 1–3).
TATI/SPINK1 immunoexpression scoring was analogous to
that of EGFR (Koskensalo 2011); for statistical analysis the
patients were divided into two groups: TATI2 (score 0) and
TATI+ (scores 1–3).
Statistical analysis
We analyzed separately EGFR staining alone and together with
TATI/SPINK1 staining (EGFR+/2, TATI+/2 or EGFR2
TATI+/2). The association between immunoexpression and
clinicopathological variables was assessed by the x2 test or Fisher’s
exact test in case of low expected frequencies. Survival was
analyzed by the Kaplan-Meier method. Statistically significant
covariates in univariate analysis were analyzed in multivariate
survival analysis by the Cox proportional hazards model. A
p,0.05 was considered significant. Statistical analyses were
performed with IBM SPSS Statistics 20.0 software.
Results
Immunostaining for EGFR
Reliable evaluation of immunostaining was possible in 520 of
the 623 samples. In 69 (13.3%), cytoplasmic EGFR immunopo-
sitivity was scored as high (3), in 172 (33.1%) as moderate (2), and
in 236 (45.4%) as weak (1), while 43 (8.3%) showed no EGFR
immunopositivity (Fig. 1). We evaluated only cytoplasmic staining,
because if cytoplasma is positive, the membrane staining is
unsuitable for reliable evaluation.
EGFR immunoreactivity associated with tumour grade; posi-
tivity was detected more often in highly and moderately
differentiated than in undifferentiated tumours (p = 0.040). EGFR
expression showed no association with Dukes’ stage, but positivity
Table 2. Patient clinicopathological characteristics and their correlation with EGFR and TATI immunoreactivity in 511 colorectal
cancer patients assessed with chi-square test
Clinicopathological variable Patients EGFR2TATI2 EGFR2TATI + p EGFR+TATI2 EGFR+TATI+ p
(n) % (n) % (n) % (n) %
Gender 0.051 0.88
Female 232 9 3.9 8 3.4 71 30.6 144 62.1
Male 279 5 1.8 17 6.1 80 28.7 177 63.4
Age 0.546 0.55
,65 years 215 7 3.3 10 4.7 58 27.0 140 65.1
$65 years 296 7 2.4 15 5.1 93 31.4 181 61.1
range 25.0–90.3, median 67.6 years
Dukes’ stage 0.482 0.21
A 79 0 0 3 3.8 22 27.8 54 68.4
B 185 3 1.6 7 3.8 51 27.6 124 67.0
C 124 6 4.8 7 5.6 37 29.8 74 59.7
D 123 5 4.1 8 6.5 41 33.3 69 56.1
Dukes’ stage 0.238 0.02
A and B 264 3 1.1 10 3.8 73 27.7 178 67.4
C and D 247 11 4.4 15 6.1 78 31.6 143 57.9
Differentiation (WHO grade) 0.184 ,0.001
1 17 0 0 1 5.9 1 5.9 15 88.2
2 347 4 1.2 14 4.0 86 24.8 243 70.0
3 125 9 7.2 7 5.6 52 41.6 57 45.6
4 21 1 4.8 2 9.5 12 57.1 6 28.6
missing 1
Histologic type 0.286 ,0.005
Adenocarcinoma 457 13 2.8 20 4.4 126 27.6 298 65.2
Mucinous carcinoma 54 1 1.9 5 9.3 25 46.3 23 42.6
Tumor location 0.546 0.76
Colon 287 7 2.4 15 5.2 89 31.0 176 61.3
Rectum 221 7 3.2 10 4.5 62 28.1 142 64.3
missing 3
doi:10.1371/journal.pone.0076906.t002
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was more often present in local (Dukes’ A–B) than in metastasized
tumours (Dukes’ C–D) (94.4% versus 88.8%, p = 0.021)(Table 1).
Simultaneous immunostaining for EGFR and TATI/SPINK1
Evaluation of immunostaining for both EGFR and TATI/
SPINK1 was possible in 511 of the 623 samples. The combination
EGFR+/TATI+ was present in 321 (62.8%), EGFR+/TATI2 in
151 (29.5%), EGFR2TATI+ in 25 (4.9%), and EGFR2/TATI2
in 14 (2.7%) patients.
EGFR+/TATI+ correlated with histology occurring more often
in adenocarcinomas than in other histological tumour types
(p = 0.005), and varied by WHO grade, being most often present
in highly and moderately differentiated tumours (p,0.001)
(Table 2).
Prognostic value of EGFR
In univariate analysis, EGFR immunoexpression (p = 0.006),
patient age (p = 0.009), WHO grade (p,0.001), and Dukes’ stage
(p,0.001) associated with prognosis. Five-year survival was 59.9%
in EGFR+ patients and 40.5% in EGFR2 patients (Table 3).
In multivariate survival analysis, EGFR (p = 0.023), patients’
age (p,0.001), Dukes’ stage (p,0.001), tumour location
(p = 0.001), and WHO grade (p = 0.033) were independent
prognostic factors (Table 4).
Prognostic role of the combination of EGFR and
TATI/SPINK1
Concomitant expression of EGFR and TATI/SPINK1 corre-
lated with prognosis, 5-year survival being 65.0% in EGFR+/
TATI+ patients, 47.7% in EGFR+/TATI2, 43.2% in EGFR2/
TATI+, and 42.4% in EGFR2/TATI2 patients
(p,0.001)(Table 4, Figure 2). High age (p = 0.009), advanced
Dukes’ stage (p,0.001), and advanced WHO grade (p,0.001)
correlated with poor prognosis (Table 5).
In multivariate survival analysis, EGFR/TATI expression
(p,0.001), age (p,0.001), Dukes’ stage (p,0.001), and location
(p = 0.003) were independent prognostic factors (Table 6).
Discussion
We recently showed that TATI is an independent prognostic
factor in colorectal cancer, high tissue expression being associated
with favourable prognosis. Here we show that concomitant
immunoexpression of EGFR and TATI is an independent
prognostic factor for favorable survival in colorectal cancer, and
it is a stronger prognostic factor than EGFR or TATI/SPINK1
alone.
In concordance with previous findings, we observed EGFR
overexpression in colorectal cancer samples, [17],[18]. EGFR
immunoexpression correlated significantly with tumour grade,
Table 3. Univariate analysis of correlations between
preoperative characteristics and survival by Kaplan-Meier
life-table and logrank test analyses.
Clinicopathological Patients
Cumulative
5-y x2 p- value
variable (n) % survival % statistic
Gender 0.002 0,964
Female 235 45.2 56.9
Male 285 54.8 60.4
Age 6.739 0.009*
,65 years 219 42.1 63.3
$65 years 301 57.9 55.5
Dukes’ stage 266.05 ,0.001*
A 81 15.6 89.0
B 188 36.2 83.1
C 126 24.2 52.4
D 125 24.0 8.2
Dukes’ stage 196.02 ,0.001*
A and B 269 51.7 84.9
C and D 251 48.3 30.7
Differentiation (WHO
grade)
12.93 ,0.001*
1 17 3.3 80.9
2 351 67.6 62.3
3 130 25.0 49.7
4 21 4.0 38.9
missing 1
Histologic type 0.751 0.386
adeno-ca 463 89.0 59.8
mucinous ca 57 11.0 51.6
2.253 0.133
Tumor locationColon 291 56.3 60.7
Rectum 226 43.7 56.8
missing 3
EGFR immunoreactivity 7.549 0.006
negative 43 8.3 40.5
positive 477 91.7 59.9
* = p-value significant.
doi:10.1371/journal.pone.0076906.t003
Table 4. Cox multivariate regression analysis of prognostic
factors in 520 colorectal cancer patients.
Covariate
Wald
statistic p-value RH 95% CI
Age 31.006 ,0.001 1.032 1.021–1.044
Dukes’ stage 285.799 ,0.001
A
B 0.519 0.471 1.259 0.673–2.357
C 29.923 ,0.001 5.084 2.839–9.103
D 123.403 ,0.001 27.601 15.371–
49.562
WHO Grade 8.276 0.041
1
2 3.579 0.058 2.619 0.966–7.103
3 5.282 0.022 3.305 1.192–9.161
4 6.197 0.013 4.341 1.366–
13.791
Tumor location in rectum 10.009 0.002 1.535 1.366–
13.791
Histologic type NS
EGFR 4.054 0.044 0.639 0.413–0.988
NS= not significant, RH= relative hazard, CI = confidence interval at 95% level.
doi:10.1371/journal.pone.0076906.t004
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being more often positive in high and moderately differentiated
tumours, as reported previously [19]. Conversely, EGFR expres-
sion has also been shown to correlate with poor differentiation
[18]. As in other studies, we found correlation with histology
[20],[21] but no correlation between EGFR immunoexpression
and Dukes’ stage. This is in concordance with the study by Giralt
[20], whereas Spano et al. reported stronger EGFR overexpression
in T3 than in T4 colorectal tumours [17]. Deng et al. found, in 94
colorectal cancer patients, an association between high expression
and high tumour stage [22].
Here we show that EGFR immunoexpression is an independent
marker for favourable prognosis in colorectal cancer patients. Our
results differ from those others’ ; EGFR expression did not
correlate with survival in a study of 249 [19] and 132 CRC
patients [17] or in 87 Dukes’ C CRC patients, [6]. However, in
some studies specifically of colon cancer, EGFR expression
correlated with poor prognosis. In a study of 149 patients, EGFR
expression was an independent marker of adverse prognosis, but
EGFR expression was observed in only 35.6% of the samples,
which is less than usually reported [23]. Resnick et al. also showed
an association between strong EGFR expression and poor
prognosis in colon cancer [24]. In a subanalysis including only
colon cancer, our study showed an association between EGFR
expression and improved survival, but the difference was not
significant (data not shown).
In a subgroup analysis of rectal cancer, we found significantly
better survival rates (p = 0.001) in patients with EGFR positivity
(data not shown). In 87 rectal cancer patients who had received
preoperative radiation therapy, Giralt et al reported EGFR
expression in pre-treatment biopsies- but not in surgical samples-
to associate with adverse prognosis [20]. In a study by Fernebro
et al. on 269 rectal cancer patients, no association was observed
with metastasis-free survival [25]. In a study of 40 rectal cancer
patients, Yasuda et al. found decreasing EGFR levels after
chemoradiotherapy, but EGFR expression was not a prognostic
marker [26]. Radiotherapy can both reduce and increase EGFR
expression [27],[20]. We did not analyze EGFR expression in pre-
treatment biopsies, but no difference in EGFR expression emerged
between rectal cancer patients receiving or not receiving
preoperative radiotherapy (data not shown).
EGFR-targeted treatments have been used for metastasized
colorectal cancers, but the value of EGFR immunoexpression to
predict the efficiency of adjuvant treatment is controversial.
Interestingly, the EGFR antagonist cetuximab has proven effective
even against EGFR-negative tumours [28]. One explanation for
this may be that anti-EGFR- treatment is targeted against
metastasized tumors, and correlation between EGFR immunoex-
pression in the primary tumor and metastatic lesion is unclear and
varies between studies [19],[29],[22]. In addition, EGFR-positive
tumors do not always respond to cetuximab treatment [30].
Furthermore, tumors with KRAS mutations have been found to
respond poorly to anti-EGFR therapy [10],[11], and the analysis
of KRAS mutational status is recommended for all metastatic
CRCs [31]. KRAS mutations in codon 12 correlates with adverse
prognosis [31,32]. BRAF is the second step of the EGFR-
mediated pathway. Mutated BRAF correlates with adverse
prognosis [33], but patients with BRAF mutation may benefit
from EGFR-targeted treatments [31]. A novel method that
appears to be superior to analysis of KRAS mutations to select
patients for anti-EGFR therapy is combined analysis of KRAS
mutations and EGFR gene copy number [34].
The PIK3CA (the phosphatidylinositol-4,5-bisphosphonate
3-kinase, catalytic subunit alpha polypeptide gene) pathway is
another downstream pathway of EGFR signalling. Mutations of
the PIK3CA gene can promote malignant transformation [35].
Use of aspirin blocks the PIK3CA pathway, and correlates with
better prognosis among patients with a mutated gene [36].
Unfortunately data on aspirin use was not available in our patient
records.
Ozaki et al. showed that EGFR and TATI/SPINK1 are co-
expressed in pancreatic cancer and that SPINK1 stimulates the
proliferation of pancreatic cancer cells through EGFR activation
Figure 2. Survival curves of concomitant expression of EGFR and TATI/SPINK1 in colorectal cancer patients.
doi:10.1371/journal.pone.0076906.g002
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[13]. Here we show that in roughly two out of three colorectal
carcinoma samples EGFR and TATI/SPINK1 are co-expressed.
We have shown earlier that high TATI/SPINK1 tissue expression
correlates with better prognosis in CRC; here we show that
concomitant expression of EGFR and TATI/SPINK1 is an even
better marker for improved survival. It is known that there are
positive and negative feedback loops within EGFR-mediated
pathways depending on cell type, and one reason for better
prognosis in colorectal cancer may be that binding of TATI leads
to inhibition of cascades leading to malignant transformation.
Also, TATI binding to EGFR may inhibit the binding of stronger
activating ligands.
It is therefore plausible that TATI/SPINK1 and the interaction
between TATI/SPINK1 and EGFR play different roles in CRC
than in pancreatic cancer.Interestingly, expression of TATI/
SPINK1 in cancer tissue is also associated with good prognosis in
gastric cancer [37] and loss of TATI/SPINK1 expression
correlates with aggressive disease in bladder cancer [38]. This
indicates that TATI/SPINK1 exerts different functions in
different pathologies. TATI/SPINK1 is not only an activator of
EGFR but also an effective trypsin inhibitor and trypsin is
expressed by several tumors [38]. Thus it is not surprising if it also
exerts different functions in different tumours. So far, EGFR
immunohistochemistry is not a tool for prediction of which
patients that are likely to benefit from EGFR-targeted adjuvant
treatment. It would be interesting to study whether adding TATI/
SPINK1 tissue analysis plus KRAS mutation analysis and EGFR
gene copy number assessment could further improve the
promising results of A˚lgars et al. [34].
In conclusion, to the best of our knowledge, we show for the first
time that concomitant immunoexpression of EGFR and TATI/
SPINK1 is an independent prognostic marker for favourable
prognosis in colorectal cancer patients. The combination is a
stronger prognostic tool than either TATI/SPINK1 or EGFR
alone. Further studies are necessary to better understand the
association between TATI/SPINK1 and EGFR in colorectal
cancer and for evaluating the potential use of this marker
combination to predict treatment response.
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Table 5. Univariate analysis of correlations between
preoperative characteristics and survival with Kaplan-Meier
life-table and logrank test analyses.
Clinicopathological Patients
Cumulative
5-year x2 p-value
variable (n) % survival % statistic
Immunoexpression 13.135 ,0.001
EGFR+TATI+ 321 62.8 65.4
EGFR+TATI2 151 29.5 48.5
EGFR2TATI+ 25 4.9 43.2
EGFR2TATI2 14 2.7 42.4
Gender 0.002 0.964
Female 235 45.2 56.9
Male 285 54.8 60.4
Age 6.739 0.009
,65 years 219 42.1 63.3
$65 years 301 57.9 55.5
Dukes’ stage 266.05 ,0.001*
A 81 15.6 89.0
B 188 36.2 83.1
C 126 24.2 52.4
D 125 24.0 8.2
Dukes’ stage 196.02 ,0.001*
A and B 269 51.7 84.9
C and D 251 48.3 30.7
WHO grade 12.93 ,0.001*
1 17 3.3 80.9
2 351 67.6 62.3
3 130 25.0 49.7
4 21 4.0 38.9
missing 1
Histologic type 0.751 0.386
adeno-ca 463 89.0 59.8
mucinous ca 57 11.0 51.6
Tumor location 2.253 0.133
Colon 291 56.3 60.7
Rectum 226 43.7 56.8
missing 3
* =p-value significant.
doi:10.1371/journal.pone.0076906.t005
Table 6. Cox multivariate regression analysis of prognostic
factors in 511 colorectal cancer patients.
Covariate
Wald
statistic p-value RH 95% CI
Age 29.817 ,0.001 1.032 1.020–1.043
Dukes’ stage 282.046 ,0.001
A
B 0.921 0.337 1.371 0.720–2.612
C 32.723 ,0.001 5.813 3.180–
10.624
D 121.32 ,0.001 30.23 16.482–
55.445
Tumor location in rectum 8.812 0.003 1.499 1.148–1.959
EGFR+TATI+ 20.691 ,0.001
EGFR+TATI2 14.556 ,0.001 1.771 1.321–2.376
EGFR2TATI+ 10.768 0.001 2.438 1.432–4.151
EGFR2TATI2 0.306 0.580 0.554 0.554–2.869
Differentiation (WHO Grade) NS
Histologic type NS
NS= not significant, RH= relative hazard, CI = confidence interval at 95% level.
doi:10.1371/journal.pone.0076906.t006
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